CompletedPhase 4ACTRN12614001086651

Effects of Fenofibrate on Intramyocardial Triglyceride Content and Left Ventricular Myocardial Function in patients with Type 2 Diabetes and Hypertriglyceridemia

Sponsor

Dr Arnold Ng

Enrollment

60 participants

Start Date

Jun 15, 2014

Study Type

Interventional

Conditions

Hypertriglyceridemia

Summary

This is a single-centre, randomized, double-blind, placebo-controlled clinical trial. Participants will be randomized to receive fenofibrate (145mg daily for 6 months) or placebo in a parallel group, double blind design. Participants will undergo a cardiac MRI, Adenosine stress MRI perfusion, echocardiography and ECG at baseline and 6 months.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Inclusion Criteria2

Type 2 diabetes
Hypertriglyceridemia

Exclusion Criteria5

Atrial fibrillation
Current use of any fenofibrate or related fibrates
Contraindication to fenofibrate including: liver impairment demonstrated by abnormal liver function tests (greater than or equal to 3 times normal upper limit), chronic renal failure (eGFR <60mL/min), symptomatic gallbladder disease, myopathy/myositis (elevation of CK > 5 times upper limit of normal)
Contraindication to MRI including use of Gadolinium contrast
Current enrolment in any other drug trial

Interested in this trial?

Get notified about updates and connect with the research team.